Filing Details
- Accession Number:
- 0001209191-14-072484
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-02 19:12:59
- Reporting Period:
- 2014-11-28
- Filing Date:
- 2014-12-02
- Accepted Time:
- 2014-12-02 19:12:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1037760 | Cepheid | CPHD | Laboratory Analytical Instruments (3826) | 770441625 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1263113 | H David Persing | C/O Cepheid 904 Caribbean Drive Sunnyvale CA 94089 | Evp, Chief Med/Tech Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-11-28 | 15,000 | $8.43 | 19,062 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-11-28 | 5,000 | $55.23 | 14,062 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-11-28 | 5,000 | $55.78 | 9,062 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-11-28 | 5,000 | $56.34 | 4,062 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified option (right to buy) | Disposition | 2014-11-28 | 15,000 | $0.00 | 15,000 | $8.43 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
10,000 | 2016-04-28 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- 25% of the shares subject to the grant vest and become exercisable on the one-year anniversary of the grant date, then 2.0833% of the shares subject to the grant vest and become exercisable each month thereafter, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.